- Home
- LEXX vs NTRB Comparison
LEXX vs NTRB Comparison
Compare LEXX & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- NTRB
- Stock Information
- Founded
- LEXX 2004
- NTRB 2016
- Country
- LEXX Canada
- NTRB United States
- Employees
- LEXX N/A
- NTRB N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- NTRB Industrial Specialties
- Sector
- LEXX Health Care
- NTRB Health Care
- Exchange
- LEXX Nasdaq
- NTRB Nasdaq
- Market Cap
- LEXX 49.3M
- NTRB 49.2M
- IPO Year
- LEXX N/A
- NTRB N/A
- Fundamental
- Price
- LEXX $3.19
- NTRB $5.89
- Analyst Decision
- LEXX Strong Buy
- NTRB
- Analyst Count
- LEXX 2
- NTRB 0
- Target Price
- LEXX $11.00
- NTRB N/A
- AVG Volume (30 Days)
- LEXX 96.5K
- NTRB 48.7K
- Earning Date
- LEXX 11-18-2024
- NTRB 09-03-2024
- Dividend Yield
- LEXX N/A
- NTRB N/A
- EPS Growth
- LEXX N/A
- NTRB N/A
- EPS
- LEXX N/A
- NTRB N/A
- Revenue
- LEXX $411,019.00
- NTRB $1,803,816.00
- Revenue This Year
- LEXX $82.02
- NTRB N/A
- Revenue Next Year
- LEXX $95.09
- NTRB N/A
- P/E Ratio
- LEXX N/A
- NTRB N/A
- Revenue Growth
- LEXX 34.05
- NTRB N/A
- 52 Week Low
- LEXX $0.85
- NTRB $1.53
- 52 Week High
- LEXX $6.85
- NTRB $9.60
- Technical
- Relative Strength Index (RSI)
- LEXX 48.73
- NTRB 53.93
- Support Level
- LEXX $2.91
- NTRB $5.70
- Resistance Level
- LEXX $3.39
- NTRB $7.74
- Average True Range (ATR)
- LEXX 0.20
- NTRB 0.67
- MACD
- LEXX 0.00
- NTRB 0.03
- Stochastic Oscillator
- LEXX 56.00
- NTRB 38.53
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.